Gout Elevation of serum uric acid level: hyperuricemia primary risk factor,predisposes to gout > 6.8mg/dl Deposition of uric acid crystals (monosodium.

Slides:



Advertisements
Similar presentations
GOUT Disease caused by tissue deposition of Monosodium urate crystals as a result of supersatuaration of extra cellular fluid with MSU.
Advertisements

1 Oxypurinol for Gout Arthritis Drugs Advisory Committee June 2, 2004 Cardiome Pharma Corp Vancouver, BC Canada.
TXF Caveat on urate levels Serum uric acid level may be normal at the time of an acute attack. Normal level does not rule out gout. May be better.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings Dee Unglaub Silverthorn, Ph.D. H UMAN P HYSIOLOGY PowerPoint ® Lecture Slide.
Purine Degradation & Gout (Musculoskeletal Block)
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Nucleic acids metabolism
Gout.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
Purine degradation & Gout (Musculoskeletal Block).
Uric Acid Mr. Mohammed O. Jaber, MLS. Uric Acid  Uric acid is formed from the breakdown of nucleic acids and is an end product of purine metabolism.
GOUT. Gout is a familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate crystals. The metatarsophalangeal.
Uric acid xiaoli.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Purine Degradation & Gout (Musculoskeletal Block)
Uric Acid Metabolism & Gout. Nucleic Acids Mononucleotide Base + Sugar + Phosphoric Acid Base: Purine or Pyrimidine Polynucleotide (DNA or RNA) Mononucleotides.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
Uric Acid Metabolism & Gout
HYPERURICEMIA and GOUT PATHOGENESIS. HYPERURICEMIA Plasma/serum urate concentration >408 mol/L (6.8 mg/dL) Present in between 2.0 and 13.2% of ambulatory.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Anti-Inflammatory & Immunosuppressive Drugs 2
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Purine degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Drug Therapy of Gout.
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Agents Used to Treat Hyperuricemia and Gout
Gout Treatment Megan Chan, PGY-2 UHCMC Gout Acute gouty arthritis = monosodium urate crystals in synovial fluid leukocytes – Serum urate ≥ 6.8 =
Metabolism of purine nucleotides
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Gout is a species-wide inborn error of purine metabolism D. Branch Moody, M.D. Professor of Medicine Immunology Laboratory, Smith Building
NSAIDs (non steroidal anti- inflammatory drugs). THE INFLAMMATORY RESPONSE 1.The inflammatory response is a normal (desirable) defense mechanism. 2.The.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
GOUTY ARTHRITIS PRESENTED BY, JISMI MATHEW LINCY K OUSEPH MEENUPRIYA OONNANAL SMITHA V CHACKO VINEETHA MARY MATHEW.
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
ANTI-GOUT DRUGS. GOUT A familial metabolic disease characterized by recurrent episodes of acute arthritis due to deposits of monosodium urate in joints.
Uric acid nephropathy 신장내과 R4 최선영. Endogenous production of uric acid Purine catabolism hypoxanthine xanthine Uric acid allantoin XO UO allopurinol -
Drugs in gout epidemiology Male to female ration 10:1 Prevalence of hyperuricemia 5% Prevalence of gout 0.2%
Purine Degradation & Gout (Musculoskeletal Block) Purine degradation pathway Fate of uric acid in humans Gout and hyperuricemia: Biochemistry Types Treatment.
Metabolism of purine nucleotides A- De Novo synthesis: of AMP and GMP Sources of the atoms in purine ring: N1: derived from NH2 group of aspartate C2 and.
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
Gout Asad Khan Consultant Rheumatologist
Gout Is recurrent inflammatory disorder characterized by
Purine degradation and Gout
Purine Degradation & Gout (Musculoskeletal Block)
Gout.
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Introduction to pathology
GOUTY ARHTRITIS.
Drug Therapy of Gout 1.
GOUT.
PURINE AND PYRIMIDINE DEGRADATION
  URIC ACID Muthana A. Al-Shemeri.
RUINS IN POMPEI, ITALY. RUINS IN POMPEI, ITALY.
Antiuricaemic drugs Dr A.W Olusanya.
Desorders of nucleotides metabolism
Treat to Target in Gout.
Gout Scott Smith PGY-1 1/11/2018.
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
Purine Degradation & Gout (Musculoskeletal Block)
Drugs in gout epidemiology Prevalence of hyperuricemia 5%
Purine Degradation & Gout (Musculoskeletal Block)
Presentation transcript:

Gout Elevation of serum uric acid level: hyperuricemia primary risk factor,predisposes to gout > 6.8mg/dl Deposition of uric acid crystals (monosodium urate) in the joint Acute inflammatory arthritis Management of the disease – Between flares Normalize urate level: goal below 6 mg/dl Maintain health joint – During flares: control and resolution of inflammation

Endogenous source: cellular break down nucleic acids Food rich in purine Purines: Hypoxanthine Guanine Xanthine Uric acid Allantoin Gastro-intestinal elimination 33% Renal elimination 66% Joint: Monosodium urate crystals Inflammation Gout Uricase: Non primates Xanthine oxidase Xanthine oxidase Guanine deaminase 2 major pharmaceutical targets: Inhibition of xanthine oxidase: e.g. allopurinol, febuxostat Increase renal uric acid excretion: e.g. probenecid Pathogenesis

Normalize urate level Gastro-intestinal tract: probiotics Inhibition of xanthine oxidase – Methanol extract of Chrysanthemum sinense (china) – Methanol extract of Larix laricinia ( North America) – Methanol extract of Coccinia grandis (India) – Methanol extract of Vitex negundo (India) – Chloroform extract of Erythrina stricta (India, China, Vietnam, Thailand) – Various plant extracts containing rutin and quercetin (Biota orientalis and others) – Cassia oil from Cinnamomum cassia Increase renal uric acid excretion: – Methanol extract of Orthosiphon stamineus – Lignans from Phyllanthus niruri ( Southeast Asia and Latin America) Mixed: (XOI and renal): Paedaria scandens ( China)

Maintain joint health DMOADs: glucosamine, chondroitin, insaponifiable fraction of soja and avocado Promotion of resolution of inflammation: DHA and EPA Plant derived anti-inflammatory agents – Curcuma – Meadowsweet – Black current

Normalize urate level Uricosuric agent and xanthase oxidase inhibitors GI tract health Probiotic Maintain joint health DMOADs DHA and EPA Plant anti-inflammatory Natural gout prevention program

Inflammation targets during gout flare Blood vessel Endothelium Synovium Resident macrophages Dendritic cells O 2 - Enzymes Complement Cytokines Apolipoproteins Clean up by macrophages Neutrophil migration Apoptosis TGFβ Monocytes Resident macrophages Inflammatory monosodium urate crystals Noninflammatory monosodium urate crystals Resolvins Protectins Maresins DHA + EPA Resolution of inflammation

Goals during flares for natural anti- inflammatory Inhibition of cytokine production: IL-1β, IL -6, IL-8 and TNF-α Neutralize oxygen radicals and enzymes produced by activated macrophages Promotes TGF β production Promote resolution of inflammation